Assets up 33.6% on funded growth, but ROE direction weakened

Total assets grew 33.6% to $218.2m and total liabilities grew 38.4% to $136.5m → $188.9m, principally on term deposits of $184.7m that fund the lending business. PBT advanced to $3.9m and NPAT to $2.8m, but equity grew only 9.1% to $29.2m, and the ROE direction has weakened.

An in-period acquisition (flagged in event overlays) reshaped segment mix: Corporate & Other revenue more than tripled to $3.0m and lifted from 5.3% to 11.9% of revenue, while the Finance segment share fell from 93.8% to 87.5%. This structural change carries a basis-discontinuity caveat over headline revenue, PBT, NPAT, payout and ROE growth comparisons.

The Board declared a final dividend of 0.43 cents per share. Combined with the 0.55 cent interim, FY25 total dividends are 0.98 cents — the first full-year payout under the recently introduced policy.

The 38.4% rise in liabilities, mostly term deposits, is what enabled the 33.6% lift in total assets. For a finance company, that funded loan-book expansion is the primary economic engine, but its quality depends on net interest margin, arrears and impairment — none of which are quantified in the supplied materials. Investors cannot yet judge whether the bigger book is earning adequately for the additional credit and funding risk taken on.

ROE direction softened despite headline growth. With equity up only 9.1% but assets up 33.6%, the business is more leveraged into a finance-company book whose returns per dollar of equity are trending lower (precise ratios carry a basis-discontinuity caveat tied to the acquisition). A weakening ROE trajectory while the balance sheet expands is a structural signal worth tracking.

Segment mix shift is acquisition-driven. Corporate & Other swung from a $0.3m segment loss to a $1.6m segment result, while Research & Advisory turned slightly loss-making at -$5.6k versus +$59.5k. Without disclosed acquisition contribution, the underlying organic Finance result (segment result $3.2m vs $2.9m) is a more cautious read than the consolidated growth figures suggest.

The HY25 half delivered 47.9% of full-year revenue but 56% of full-year NPAT, which implies a softer second-half earnings shape: roughly $1.2m of implied 2H NPAT against $1.6m in HY25, despite revenue lifting from $10.8m to $11.8m. This is consistent with acquisition-related transaction or integration costs absorbing margin in the back half, but the release does not isolate the driver.

Investors have no disclosed benchmark to test FY25 against. The release does not provide loan-book size, arrears rate, NIM, or provision coverage, all of which are needed to judge whether the larger balance sheet is translating into durable, risk-adjusted earnings.

Net cash from operating activities of $41.4m versus $4.2m principally reflects movements in deposits and loans — the funding/lending mechanics of the business — rather than profit-driven cash conversion. Sector convention requires separating those funding flows from underlying earnings quality, and the supplied materials do not provide that breakdown. Capex of $0.5m (2.1% of revenue) simply confirms the business is balance-sheet-led, not capex-led.

On the underlying read, the Finance segment lifted from $2.9m to $3.2m of segment result — a modest organic step-up in the core lending franchise. The remainder of the consolidated improvement sits in Corporate & Other, where the swing from -$0.3m to +$1.6m looks unusual and likely reflects acquisition-period accounting. The basis-discontinuity caveat means reported revenue, PBT and NPAT growth percentages should not yet be treated as clean trend evidence until a full post-acquisition comparable cycle is reported.

This briefing cannot assess whether the expanded loan book is being grown at adequate risk-adjusted returns, because net interest margin, arrears and impairment data are not disclosed in the supplied materials.